A prospective, open label, pilot study to compare ECG electrical signals of EG Holter PX3.0 with Bittium Faros 360 (3 channel lead-set with 5 electrodes) ECG Holter to evaluate equivalence via analysis using FDA approved Bittium software without intended use in arrythmia(s) treatment

Traditional ECG recordings involve placing electrodes on specific locations on the chest, which can be cumbersome and limit patient mobility. Ambulatory ECG monitoring, also known as Holter monitoring, addresses this limitation by allowing for continuous ECG recording over an extended period, typically 24 to 72 hours, allowing the patient to undergo its daily routine activities. This study aims to compare the signal quality and performance of a novel ECG Holter device, the EG Holter PX3.0, against a well-established and FDA-approved device, the Bittium Faros 360. In response to the challenge associated with the conventional ECG monitoring, there is a growing need for alternative monitoring options that address issues of inconvenience and restricted patient activity. If demonstrated to be comparable to current devices, the EG Holter PX3.0 may provide patients undergoing Holter monitoring with a more pleasant and convenient option. Since the EG Holter PX3.0 (assessment of a novel Japanese technology) is a relatively new gadget, it is necessary to assess how well it performs in comparison to the industry standard, the Bittium Faros 360. Data collection as results of this study on analysis can help with future research and development activities connected to the EG Holter PX3.0 and its possible uses in arrhythmia management, even if the study does not intend to use the collected data for arrhythmia diagnosis or treatment.